patent.fyi
Applications  /  US 2026/0355164
United States Patent Application Publication

US 2026/0355164 A1

Published
Nov 12, 2026
Filed
Jul 28, 2023
Earliest date on the face
Jul 30, 2022
Classification
A61K 31/423
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Renal glucose transport inhibition

What ifWhat if the treatment uses a renal sodium–glucose cotransporter 2 inhibitor for heart failure with preserved ejection fraction?
Claim language“a Jun inhibitor”

An oral small molecule reduces glucose and sodium reabsorption in the proximal renal tubule. This treatment reduces the rate of worsening heart failure events in patients with preserved ejection fraction.

1.1Mineralocorticoid receptor blockade

What ifWhat if the treatment uses a nonsteroidal mineralocorticoid receptor antagonist?
Claim language“a Jun inhibitor”

An oral small molecule blocks aldosterone-dependent activation of the mineralocorticoid receptor. In symptomatic heart failure with a left ventricular ejection fraction of at least 40 percent, this treatment reduces worsening heart failure events.

1.1Incretin therapy for obesity

What ifWhat if the treatment uses a dual incretin receptor agonist in patients with obesity and heart failure with preserved ejection fraction?
Claim language“a Jun inhibitor”

A weekly subcutaneous peptide activates receptors for glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. The regimen reduces body weight and improves heart failure symptom scores in this population.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Small interfering RNA targeting JUN

A synthetic small interfering RNA duplex replaces the small-molecule or peptide inhibitor in an injectable formulation. The duplex contains a guide strand complementary to a region of human JUN messenger RNA shared by the transcripts expressed in the target cells. An ionizable lipid nanoparticle carries the duplex, and cells that take it up and release it into the cytosol use the guide strand to direct cleavage of JUN messenger RNA.

Specific version of a part

Supervised aerobic exercise

A stable patient completes scheduled walking or stationary cycling sessions at an intensity set using a baseline exercise test. Repeated training improves peak oxygen uptake and functional capacity in patients with preserved ejection fraction.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 7,141,238 B2
Published
Nov 28, 2006
Filed
Oct 22, 2003
Class
A61K 7/42
Document BUS 2021/0330694 A1
Published
Oct 28, 2021
Filed
Jul 6, 2021
Class
A61K 31/732
Claim 1
Document A
Document B
1.1administering to a subject in need thereof an effective amount of a Jun inhibitor.
This UV-induced inhibition of the synthesis of collagen can be prevented by the topical application of a retinoid or c-JUN inhibitor to the skin prior to exposure to UV radiation.
A · US 7,141,238 B2 · abstract
A method for treating diastolic heart failure (heart failure with preserved ejection fraction (HFpEF)) in a subject in need thereof is provided including administering a therapeutically effective amount of a galectin-3 inhibitor to the subject.
B · US 2021/0330694 A1 · abstract

An empty cell means only that no passage was reproduced there.

Statements in these documents
More particularly, the invention relates to compositions and methods for this use by topical application to reduce if not eliminate the inhibition of collagen synthesis in human skin after incidental and/or direct exposure to UV radiation as would occur daily, and as would occur after recreational exposure to UV radiation during a planned, extended period in the sun.
A · US 7,141,238 B2 · ¶ 3
Photoaging is a term presently used to describe the changes in appearance and/or function of human skin as a result of repeated exposure to sunlight, and especially in reference to wrinkles and other changes in the appearance of the skin thought to be related to exposure to the sun.
A · US 7,141,238 B2 · ¶ 7
Embodiments relate to treating diastolic heart failure by inhibiting galectin-3.
B · US 2021/0330694 A1 · ¶ 2
Identifying effective therapies to treat diastolic HF is a major unmet need in the United States and worldwide.
B · US 2021/0330694 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355164 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355164/, SHA-256 8131fb9af0ca9b4947a797629fd16398d2161b75435c7268153d4b8618de2202
First published
Permanent addresshttps://patent.fyi/US20260355164/
Content fingerprint (SHA-256)8131fb9af0ca9b4947a797629fd16398d2161b75435c7268153d4b8618de2202
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi